Oyster Therapeutics closes $60m Series A-2 for brain-penetrant protein degraders
4BIO Capital leads the financing, joined by Eli Lilly, CE-Ventures, Actium Group, TOHO Ventures and returning investors.
Oyster Therapeutics announced a $60 million Series A-2 financing on November 10, led by 4BIO Capital. Eli Lilly and Company, CE-Ventures, Actium Group and TOHO Ventures joined as new investors, alongside Syncona, Oxford Science Enterprises, Mission BioCapital and Mass General Brigham Ventures.
The financing accompanies the company’s change of name from Kesmalea Therapeutics to Oyster. Its lead oral tau-degrader programme is being prepared for clinical development, with the aim of treating diseases such as Alzheimer’s.
Oyster has also signed a sponsored research agreement with Massachusetts General Hospital. The collaboration gives it access to patient-derived neuronal models and methods for studying abnormal tau under researcher Catarina Silva, supporting the work to take its lead programme towards the clinic.
Use of funds
Advance the oral brain-penetrant tau degrader into clinical development
Develop the SELFTAC targeted protein degradation platform
Funding history
Sources
- 次世代標的タンパク質分解剤を開発するOyster Therapeutics Limitedへ出資 | グローバル・ブレイン株式会社のプレスリリースprtimes.jp · Nov 10, 2026
- Oyster announces $60m Series A financingbiosolutions.org.uk · Nov 10, 2026
- 4BIO Capital leads Oyster financing4biocapital.com · Nov 10, 2026
- CE-Ventures backs UK's Oyster Therapeutics in $60 million Series A roundwamda.com · Nov 11, 2026